Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Pathol. 2010 Mar;176(3):1462-8. doi: 10.2353/ajpath.2010.090875. Epub 2010 Jan 21.

Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to bladder cancer progression.

Author information

1
Department of Urology, University of Michigan, 3875 Taubman Center Box 0330, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0330, USA.

Abstract

Prostaglandin E2, which is known to contribute to cancer progression, is inactivated by the catabolic enzyme, 15-hydroxyprostaglandin dehydrogenase (PGDH), which has tumor-suppressor activity in lung, colon, breast, and gastric cancers. Therefore, we evaluated the expression of PGDH in human bladder cancer tissue specimens and cell lines. Immunoperoxidase staining of bladder cancer tissues demonstrated that (1) PGDH is highly expressed by normal urothelial cells but (2) reduced in many low stage (Ta/Tis) bladder cancers, and (3) PGDH is completely lost in most invasive bladder cancers. Of eight cancer cell lines tested, only two relatively well-differentiated bladder cancer cell lines, RT4 and UM-UC9, expressed PGDH. Moreover, inhibition of PGDH expression in well-differentiated RT4 cells using small inhibitory RNA or short hairpin RNA resulted in a more aggressive phenotype with increased motility and anchorage-independent growth. Additionally, PGDH knockdown affected prostaglandin E2 signaling as measured by cAMP generation. These data indicate that loss of PGDH expression contributes to a more malignant bladder cancer phenotype and may be necessary for bladder cancer development and/or progression.

PMID:
20093479
PMCID:
PMC2832165
DOI:
10.2353/ajpath.2010.090875
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center